|
|
Publication Archive |
|
|
 |
|
March Madness
Capital Ideas
By: K. Lloyd Billingsley
3.24.2004
On March 15, some 5,000 community college students, more by some counts, descended on California's capitol, hoisting signs, denouncing the governor and bellowing that they had been betrayed. The casual observer might have wondered if this was a protest against the war in Iraq. Turns out, it was something else.
Read more
|
|
|
The Scary Future
Capital Ideas
By: Lance T. Izumi, J.D.
3.18.2004
The controversy over American jobs going overseas has so far largely overlooked the key factor of poor-quality American education. American companies, faced with a domestic labor pool deficient in even basic knowledge and skills, are financing the math and science education of students in foreign countries. Yet, despite the implications of this trend, California has reduced the difficulty of math requirements for students.
Read more
|
|
|
The "Violence of Egotism'' and the Strange Case of Ralph Nader
Capital Ideas
By: Steven F. Hayward, Ph.D
3.3.2004
Ralph Nader's utterly predictable announcement that he will indeed run for president again as an independent candidate summons forth a certain amount of schadenfreude among Republicans, as well it should. After all, it was liberal Democrats, along with a fawning and credulous media, that swelled Nader's fame beyond all legitimate proportion back in the 1960s and 1970s.
Read more
|
|
|
The Potential Impact of the Medicare Prescription Drug Benefit on Pharmaceutical Companies
PRI Study
By: PricewaterhouseCoopers , Health Policy Economics
3.1.2004
On December 8, 2003, the President signed the Medicare Prescription Drug Coverage, Improvement, and Modernization Act of 2003, which added a prescription drug benefit as part of the Medicare program starting in 2006. The impact of the legislation on pharmaceutical industry profits is the subject of some controversy. A recent study by academics estimates that the Medicare prescription drug benefit would increase profits in the pharmaceutical industry by $139 billion, or 38 percent, between 2006 and 2013. The study, written by Alan Sager and Debora Socolar of Boston University, has been widely quoted by critics of the recently enacted Medicare legislation. These results stand in stark contrast to the opinion of financial analysts who track developments in the pharmaceutical industry.
Read more
|
|
|
|
 |